# A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

> **NCT01966224** · PHASE1 · COMPLETED · sponsor: **Immunomic Therapeutics, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection

## Key facts

- **NCT ID:** NCT01966224
- **Lead sponsor:** Immunomic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966224, "A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01966224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*